title: Investigation of the metabolites of (S,S)-[(11)C]MeNER in humans, monkeys and rats.
abstract: BACKGROUND
  (S,S)-[(11)C]MeNER ((S,S)-2-(alpha-(2-[(11)C]methoxyphenoxy)benzyl)morpholine) is a positron emission tomography (PET) radioligand recently applied in clinical studies of norepinephrine transporters (NETs) in the human brain in vivo. In view of further assessment of the suitability of (S,S)-[(11)C]MeNER as a NET radioligand, its metabolism and the identity of the in vivo radiometabolites of (S,S)-[(11)C]MeNER are of great interest.
  
  
  METHODS
  Thus, PET studies were used to measure brain dynamics of (S,S)-[(11)C]MeNER, and plasma reverse-phase radiochromatographic analysis was performed to monitor and quantify its rate of metabolism. Eighteen healthy human volunteers, five cynomolgus monkeys, and five rats were studied.
  
  
  CONCLUSIONS
  In human subjects, the plasma radioactivity representing (S,S)-[(11)C]MeNER decreased from 88 +/- 5% at 4 min after injection to 82 +/- 7% at 40 min, while a polar radiometabolite increased from 3 +/- 3% to 16 +/- 7% at the same time-points, respectively. A more lipophilic radiometabolite than (S,S)-[(11)C]MeNER decreased from 9 +/- 5% at 4 min to 1 +/- 2% at 40 min. In monkeys, plasma radioactivity representing (S,S)-[(11)C]MeNER decreased from 97 +/- 2% at 4 min to 74 +/- 7% at 45 min, with a polar fraction as the major radiometabolite. A more lipophilic radiometabolite than (S,S)-[(11)C]MeNER, constituted 3 +/- 2% of radioactivity at 4 min and was not detectable later on. In rats, 17 +/- 4% of plasma radioactivity was parent radioligand at 30 min with the remainder comprising mainly a polar radiometabolite. (S,S)-[(11)C]MeNER in rat brain and urine at 30 min after injection were 90% and 4%, respectively. On a brain regional level, parent radioligand ranged from 87.5 +/- 3.9% (57.2 +/- 14.2% SUV [standard uptake values, %injected radioactivity per mL multiplied with animal weight (in g)]; cerebellum) to 92.9 +/- 1.8% (36.1 +/- 4.7% SUV; striatum), with differential distribution of the radiometabolite in the cerebellum (6.7 +/- 0.3% SUV) and the striatum (2.5 +/- 0.3% SUV). Liquid chromatography-mass spectrometry analysis of rat urine identified a hydroxylation product of the methoxyphenoxy ring of (S,S)-MeNER as the main metabolite. In the brain, the corresponding main metabolite was the product from O-de-methylation of (S,S)-MeNER. PET measurements were performed in rats as well as in wild-type and P-gp-knock-out mice. In rats, the brain peak level of radioactivity was found to be very low (65%SUV). In mice, there was only a small difference in peak brain accumulation between P-gp knock-out and wild-type mice (145 vs. 125%SUV) with the following rank order of regional brain radioactivity: cerebellum x thalamus > cortical regions > striatum.
  
  
  CONCLUSIONS
  It can be concluded that radiometabolites of (S,S)-[(11)C]MeNER are of minor importance in rat and monkey brain imaging. The presence of a transient lipophilic radiometabolite in peripheral human plasma may induce complications with brain imaging, but its kinetics appear favorable in relation to the slow kinetics of (S,S)-[(11)C]MeNER in humans.
authors.affiliation: Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden. magnus.schou@astrazeneca.com
authors.forename: Magnus
authors.initials: M
authors.lastname: Schou
authors.forename: Sami S
authors.initials: SS
authors.lastname: Zoghbi
authors.forename: H Umesha
authors.initials: HU
authors.lastname: Shetty
authors.forename: Evgeny
authors.initials: E
authors.lastname: Shchukin
authors.forename: Jeih-San
authors.initials: JS
authors.lastname: Liow
authors.forename: Jinsoo
authors.initials: J
authors.lastname: Hong
authors.forename: Bengt A
authors.initials: BA
authors.lastname: Andrée
authors.forename: Balázs
authors.initials: B
authors.lastname: Gulyás
authors.forename: Lars
authors.initials: L
authors.lastname: Farde
authors.forename: Robert B
authors.initials: RB
authors.lastname: Innis
authors.forename: Victor W
authors.initials: VW
authors.lastname: Pike
authors.forename: Christer
authors.initials: C
authors.lastname: Halldin
mesh_terms: D000818:Animals; D001769:Blood / Q000000981:diagnostic imaging / Q000378:metabolism; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism; D002853:Chromatography, Liquid; D006801:Humans; D007553:Isotope Labeling / Q000379:methods; D007700:Kinetics; D008252:Macaca fascicularis; D008297:Male; D013058:Mass Spectrometry; D051379:Mice; D018345:Mice, Knockout; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000378:metabolism*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000097:blood / Q000378:metabolism* / Q000652:urine; D051381:Rats; D017207:Rats, Sprague-Dawley; D013788:Thalamus / Q000000981:diagnostic imaging / Q000378:metabolism; D014018:Tissue Distribution
chemical_list: D050484:Norepinephrine Plasma Membrane Transport Proteins; D019275:Radiopharmaceuticals
references.citation: Drug Metab Dispos. 1999 Nov;27(11):1334-40
references.pmid: 10534319
references.citation: J Nucl Med. 2006 Mar;47(3):520-7
references.pmid: 16513622
references.citation: Nucl Med Biol. 2003 Feb;30(2):85-92
references.pmid: 12623106
references.citation: Nucl Med Biol. 2003 Oct;30(7):707-14
references.pmid: 14499328
references.citation: Synapse. 2003 Dec 15;50(4):345-52
references.pmid: 14556239
references.citation: J Nucl Med. 1983 Nov;24(11):1030-8
references.pmid: 6605416
references.citation: J Comp Neurol. 1991 Feb 15;304(3):419-34
references.pmid: 2022757
references.citation: J Pharmacol Exp Ther. 1992 Jan;260(1):427-36
references.pmid: 1731049
references.citation: Cell. 1994 May 20;77(4):491-502
references.pmid: 7910522
references.citation: Eur Neuropsychopharmacol. 1997 Apr;7 Suppl 1:S23-35; discussion S71-3
references.pmid: 9169308
references.citation: Nucl Med Biol. 1998 Apr;25(3):215-23
references.pmid: 9620626
references.citation: Exp Toxicol Pathol. 1999 Jul;51(4-5):392-6
references.pmid: 10445403
references.citation: Prog Neurobiol. 2005 May;76(1):22-76
references.pmid: 16011870
references.citation: J Nucl Med. 2005 Sep;46(9):1505-15
references.pmid: 16157534
references.citation: Neuroscience. 2006;138(2):703-14
references.pmid: 16427744
references.citation: Chem Pharm Bull (Tokyo). 2001 Feb;49(2):147-50
references.pmid: 11217099